Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Roles at http://pharmaceuticalintelligence.com

Research Category OWNER:

PRABODH KANDALA, PhD, MBA

135 Trumbell Circle, Morrisville, NC 27560
Phone: 732-789-7699; e-mail: Prabodh.kandala@gmail.com

Personal Bio – Updated on 7/15/2021 by Srinivas Sriram and Abhisar Anand

SUMMARY:

• Pharmaceutical/Biotech development leader in fast-paced, dynamic and innovative organizations.
• Experience in regulatory affairs, drug development, Non-Clinical, large and small molecule CMC (Chemistry, Manufacturing and Controls) development, process development, CMC regulatory documentation, clinical supplies manufacture and distribution, technology transfer, scale-up, registration and validation.
• Experience with IND/NDA/BLA documentation, regulatory strategy, global regulatory submissions, regulatory authority interactions, due diligence, CMC strategy development and external sourcing.
• An interdisciplinary research scientist with over 9 years of experience in the Bio-Pharmaceutical Industry and hands on working experience in drug discovery and development.
• An industry professional with in-depth understanding of FDA/ICH guidelines and GLP/GMP.
• A published scientist with a record of 10 peer reviewed publications and 24 national/international conference presentations.

EDUCATION: 

• Executive MBA, Quantic School of Business and Technology      

(2019-2020)

• PhD in Pharmaceutical Sciences, Texas Tech University Health Sciences Center.                                  

(2007-2012)

• B.S. Pharmacy, Osmania University, Hyderabad, India                                                                                  

(2003-2007)

CERTIFICATES:

• Hands on cGMP Bio-manufacturing of Vectors for Gene Therapy, NCSU (2019)

      (Vector cloning, transfection, bioreactor operations up to 50 L,  process control, vector harvest,

       depth filtration for lysate clarification, ultrafiltration and buffer exchange, chromatographic purification)

• Cell Culture Engineering, North Carolina State University (NCSU)  (2018)

       (Hands on training on upstream cell culture-Fed batch, perfusion batch, scale up to 50L, 

          media preparation, harvest operations)

• Manufacturing of Biologics, Harvard Edx  (2016)

         (Vector cloning, transfections, master and working cell banks, upstream, downstream processing and 

         drug product formulation)

PROFESSIONAL EXPERIENCE:

Regulatory Affairs, IQVIA Biotech, Morrisville, NC

Manager, Regulatory Affairs

January 2020 – Present

• Managed activities of regulatory affairs with emphasis on regulatory strategy and the preparation, review and submission of the documents to FDA and other regulatory authorities (Canada, EU, APAC), including FDA meeting support.
• Provided regulatory advice to multidisciplinary teams on the regulatory requirements to support CMC development, including preparation and maintenance of IND and CTA filings.
• Written, compiled, reviewed, and approved high quality Non-clinical and CMC modules for development applications, and amendments, for submission, ensuring complete Non-clinical and CMC content that meets current regulation requirements and FDA/EU/WHO requirements.
• Lead multidisciplinary teams in the development and authoring of majority regulatory documents such as initial IND/CTA applications, IND/CTA amendments, meeting requests, meeting packages and IMPD etc.
• Served as regulatory lead with external and internal clients, as needed.
• Maintained effective communication with customer and project team through oral and written correspondence, regulatory status reports as defined. Reported progress, challenges, issues, actions and support required.
• Designed, developed and updated SOP for all US or EU regulatory affairs functions.
• Developed project timelines, strategic goals with staff and provided guidance as needed for completion of tasks. Directed the performance of the regulatory affairs staff. 
• Assured that RA functions interface effectively with all other key operating departments within IQVIA Biotech.
• Collaborated with HR in recruiting and hiring qualified regulatory staff for IQVIA Biotech projects.
• Maintained current knowledge of FDA and/or EU regulations, and GCP and ICH Guidelines for clinical research.
• Participated in Business Development activities to grow IQVIA Biotech business.

CMC (Chemistry, Manufacturing Controls), Roivant Sciences (Metavant/Enzyvant), Durham, NC

Sr. Scientist/Director/Consultant        

March 2018 –January 2020

• Authored and reviewed technical sections (CMC) for company’s global regulatory submissions (INDs, IMPDs, NDA/BLA’s, meeting requests, briefing documents, responses to Health Authority questions, etc.).
• Authored module 2 QOS and module 3 documents for regulatory submissions
• Contributed toward developing CMC and overall regulatory strategy, performing gap analysis and defining TPP.
• Led the phase appropriate pharmaceutical development of biopharmaceutical candidates from preclinical, phase 1 through phase 3 towards NDA.
• Provided regular updates to executive leadership and overall development team on budgets, timelines and strategies of drug product development.
• Managed development and manufacturing activities including pre-formulation, formulation development, process optimization using DOE, technology transfer conducted through CDMO’s/CRO’s in a variety of dosage forms.
• Directed development of phase-appropriate quality control strategies for drug products. Ensured that testing acceptance criteria were based on critical quality attributes and developed phase appropriate processes based on identification of critical process parameters (CPP). 
• Liaised with cross-functional teams including QA, pre-clinical, clinical and other CMC functions supporting formulation development and clinical studies.
• Managed supply chain for timely packaging, labeling and distribution of clinical supplies.
• Contributed technical CMC expertise in support of the company’s due diligence and life cycle management activities.
• Managed budgets for CMC Drug Product development from Phase 1 till NDA submission.
• Collaborated with non-clinical, clinical and regulatory departments for timely submission of IND updates and overall clinical program planning.
• Volunteered for CMC Project Management activities. 

ADT Formulation, Catalent Pharma Solutions, Somerset, NJ

Senior Scientist                                                                                                                         

November 2016-March 2018

Scientist                                                                                                                               

January 2015-October 2016

• Prepared CMC regulatory documents for client’s ANDA/NDA FDA submissions.
• Authored and reviewed protocols (scale up, pre-engineering, engineering, characterization, bulk hold, stability) and batch manufacturing records, product development reports, QOS, module 2 (i.e. Quality Overall Summaries) and module 3 for regulatory submissions.
• Responsible for a broad range of activities in product and process development including process transfer, scale-up activities and validations.
• Involved in risk assessment exercises and defining Critical Material Attributes, Quality Target Product Profile for dosage form and Critical Process Parameters for process.
• Developed and implemented holistic processes and procedures to enable efficient and optimal operation of different manufacturing processes.
• Optimized dosage forms using DoE (Minitab 16)
• Provided support to QA for manufacturing activities involving equipment, processes and cleaning procedures.
• Interpreted and evaluated analytical results, and communicated necessary recommendations for action.
• Led and managed client communication.
• Prepared reports and presentations on project progress as well as specifications, procedures, and SOPs
• Kept abreast of scientific literature relevant to latest technologies.
• Provided technical oversight of process development projects involving new technology introductions.
• Worked on 3 development projects and one tech transfer project.
• Nominated for QPDRA STAR Award

Jubilant Cadista Pharmaceuticals Inc., Salisbury, MD 

Scientist                                                                                                                                       

January 2014- January 2015

• Prepared and reviewed regulatory documents (ANADA, module 2 and 3 submissions, CBE-30, annual reports).
• Formulated oral solid dosage forms.
• Involved in many phases of product development including technical transfers and validation processes.
• Authored and reviewed pre-validation, validation and stability protocols, batch records for exhibit batches and intended commercial batches, PDR for FDA submissions.

RiconPharma LLC, Denville, NJ 

Assistant Scientist                                                                                                                     

June 2012- December 2013

• Prepared and reviewed regulatory documents (ANDA module 2 and 3 submissions).
• Developed a variety of pharmaceutical dosage forms including oral solids and semi-solids
• Involved in many phases of product development including technical transfers and validation processes.
• Prepared and reviewed pre-validation, validation and stability protocols, batch records for exhibit batches and intended commercial batches, PDR for FDA submissions.
• Characterized new dosage forms and formulations by utilizing prior scientific knowledge, patent searches, and scientific literature.
• Optimized dosage forms using DoE (StatEase software)
• Worked with other disciplines such as quality assurance, quality control, and regulatory affairs for successful product development.
• Analyzed analytical and clinical pharmacokinetic data to drive formulation development and design.
• Led and managed client communications.
• Developed scale up and manufacturing process by identifying and establishing critical process parameters.
• Stayed up to date with FDA and ICH guidelines, current industry trends and scientific knowledge.

TTUHSC, Amarillo, TX 

Research Assistant, Pre-Clinical Oncology                                                                                                       

2007-2012

• Performed research on cancer signaling pathways involved in cancer cell survival, apoptosis, anoikis, autophagy, EMT, angiogenesis and metastasis. 
• Pre-clinical evaluation of potential anti-cancer compounds targeting growth and metastasis of various cancers in vivo by using xenograft and orthotopic models.
• Identified various molecular targets in cancer cells by using several cellular, molecular and analytical techniques in 10 different projects. Lead investigator in 7 of these projects.
• Gained expertise in publication writing, grant writing, book editing and SOP writing.
• Published 10 papers in high impact journals and presented 24 posters in various national and international conferences.
• Honored with several awards such as Young Researcher, Dean’s Scholar and travel scholarships every year.

PUBLICATIONS: (http://www.ncbi.nlm.nih.gov/pubmed?term=kandala%20pk)

1. Kandala PK and Srivastava SK (2012). Gli1 suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. J Biol Chem 2012, 287 (34): 28745-54.
2. Kandala PK and Srivastava SK. Diindolylmethane suppress ovarian cancer growth and potentiate the effect of cisplatin in tumor mouse model by targeting STAT-3. BMC Medicine 2012, 10:9: 1-18. 
3. Kandala PK and Srivastava SK (2012). Diindolylmethane induces autophagy by activating ER stress and AMPK Oncotarget 2012, 3 (4): 435-49.
4. Loganathan SK^*, Kandala PK^*, Gupta P and Srivastava SK (2012). Inhibition of EGFR-Akt axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. PLoS ONE 2012, 7 (8): e43577.
5. Kandala PK and Srivastava SK (2012). JAK2 is a target of diindolylmethane in reducing the survival of ovarian cancer. Drug Discoveries and Therapeutics 2012, 6 (2): 94-101.
6. Kandala PK and Srivastava SK. Blocking EGFR activation suppresses ovarian tumor growth in vitro and in vivo. J. Pharm and Exp Ther. 2012, 341:1-9.
7. Kandala PK, Srivastava SK. Activation of checkpoint kinase 2 by 3,3′-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol. 2010 Aug;78(2):297-309.
8. Batra S, Sahu RP, Kandala PK, Srivastava SK. Benzyl Isothiocyanate-Mediated Inhibition of Histone Deacetylase Leads to NF-KB Turnoff in Human Pancreatic Carcinoma Cells. Mol Cancer Ther. 2010 Jun;9(6):1596-608.
9. Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK. The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol. 2010 Sep 17. 
10. Vad NM, Kandala PK, Srivastava SK, Moridani MY. Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chemico-Biological Interactions. 2010 Feb 12;183(3):462-71. 

Personal BIO – Old Content

prabodh.kandala@gmail.com

I am an experienced biomedical scientist with substantial experience in preclinical research with a focus on target identification, characterization and validation.

I am very enthusiastic to use my training and research experience in identifying novel targets and strategies for prevention or treatment of cancer and other diseases through elucidating signal transduction pathways.

I have a sound knowledge in cancer biology and pharmacology. I have experience with wide variety of cell cultures, microbiology techniques. I am adept at handling wide variety of in vitro techniques. I am equally good at working with animals. I have a wide horizon of techniques. Importantly, I am willing to learn new things.

Specialties

Signal transduction, Mammalian cell culture, Cytotoxicity assays, flowcytometry, transient and stable transfections, Plasmid extraction, DNA, RNA and protein isolation, PCR, gel electrophoresis, Immunoprecipitation, Metastasis, angiogenesis, anoikis, autophagy assays. In-vivo efficacy of drugs in tumor models, tumor implantation in mice (xenograft and orthotopic), treatment (subcutaneous, intraperitoneal and topical route), tail vein injections, tissue and blood collection

PRABODH K. KANDALA, PhD

PROFESSIONAL EXPERIENCE

 

Research Assistant

Texas Tech University Health Sciences Center (2007-2012)

 Field of study is translational research and major focus is on chemoprevention of various cancers by elucidating signal transduction pathways that get altered in response to various anti-cancer agents.

Teaching Assistant in Drug Delivery Systems

Texas Tech University Health Sciences Center (2007-2009)

Mentored Pharm.D students on laboratory practices of various pharmaceutical formulations.

Teaching Assistant in Case Studies

Texas Tech University Health Sciences Center (2009-current)

Guided Pharm.D students about pharmacodynamics and ADME pathways of several drugs used to treat various diseases.

 

EDUCATIONAL QUALIFICATION

 

Doctor of Philosophy in Biomedical Sciences

School of Pharmacy, Texas Tech University Health Sciences Center (2007-2012 )

GPA: 3.7

Bachelor of Pharmaceutical Sciences

Osmania University (2003-07)

GPA: 4.0

 

Ph.D Thesis focus

1.         Pre clinical drug discovery and target identification focused on various signal transduction pathways.

2.         Apoptosis, angiogenesis, invasion, cell cycle, autophagy and anoikis.

3.         Evaluation of anti-cancer drugs for their effects on xenograft and orthotopic in vivo models.

Experimental Techniques and Research Experience

Cancer cell models: Ovarian, pancreatic, breast, melanoma, lung, colon and prostate cancers.

Molecular biology: Mammalian cell culture, Cytotoxicity assays, cell cycle, apoptosis, autophagy, anoikis assays, survival studies, Transient transfection studies, Plasmid extraction, DNA and RNA extraction, Protein extraction, Stable transfection, Polymerase chain reaction, siRNA transfection, Agarose gel electrophoresis, Western blotting, Aortic ring assay, Invasion assay, Wound healing assay, Immunoprecipitation, Kinase activities, ROS assays.

 

Pharmacological studies (in-vivo): In-vivo efficacy of various anti-cancer drugs in tumor models, IVIS Caliper Life Sciences in-vivo imager, tumor implantation in mice, treatment (subcutaneous, intraperitoneal and topical route), tail vein injections.

 

Analytical techniques: UV-Vis spectroscopy, Drug distribution studies in tumors and tissues, Flowcytometry (Apoptosis, cell cycle analysis, mitochondrial membrane potential, autophagy detection, calcium measurements, detection of ROS), UV spectrophotometer, Fluorimetry.

Toxicological studies (in-vivo): Tissue collection (lung, liver and kidney specimens), ALT, AST.

Microscopy: Light microscopy, Immunohistochemistry, Immunofluorescence, Immunocytochemistry.

Computer Skills

  Languages: SAS (Statistical Analysis Software), C/C ++

  Software: Imaging and scanning by using Photoshop, Graph pad Prism, NIH Image J software, ChemDraw.

  Well versed in using MS Word, Excel and Power Point.

Honors and Awards

 

• GSBS Outstanding Graduate Student Award- 2012
• GSBS Dean’s Scholar award 2009-2012.
• Accuri flowcytometers AACR travel scholarship award 2011.
• Mary Lou Clements Scholarship 2011.
• TTUHSC Research Days-Best presentation award – 2011.
• Mary Lou Clements Scholarship 2010.
• Outstanding GSAA student award 2010.
• TTUHSC Research Days-Best presentation award – 2010.
• GSAA travel award-2010.
• “Young Researcher Award” at the “International Symposium on Cancer Chemorprevention and Translational Research” at School of Life Sciences, Jawaharlal Nehru University, New Delhi, India in 2009.
• GSAA travel award-2011.

 

PEER REVIEWED PUBLICATIONS

 

Accepted manuscripts:

• Kandala PK and Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting STAT-3. BMC Medicine 2012, 10:9: 1-18.
• Kandala PK and Srivastava SK. Blocking EGFR activation suppresses ovarian tumor growth in vitro and in vivo. J. Pharm and Exp Ther. 2012, 341:1-9.
• Kandala PK, Srivastava SK. Activation of checkpoint kinase 2 by 3,3′-diindolylmethane is required for causing G2/M cell cycle arrest in human ovarian cancer cells. Mol Pharmacol. 2010 Aug;78(2):297-309.
• Batra S, Sahu RP, Kandala PK, Srivastava SK. Benzyl Isothiocyanate-Mediated Inhibition of Histone Deacetylase Leads to NF-KB Turnoff in Human Pancreatic Carcinoma Cells.Mol Pharmacol. 2010 Aug;78(2):297-309.
• Sahu RP, Batra S, Kandala PK, Brown TL, Srivastava SK. The role of K-Ras gene mutation in TRAIL-induced apoptosis in pancreatic and lung cancer cell lines. Cancer Chemother Pharmacol. 2010 Sep 17.
• Vad NM, Kandala PK, Srivastava SK, Moridani MY. Structure-toxicity relationship of phenolic analogs as anti-melanoma agents: An enzyme directed prodrug approach. Chemico-Biological Interactions. 2010 Feb 12;183(3):462-71. Epub 2009 Nov 26.

Manuscripts under processing:

 

• Kandala PK and Srivastava SK (2012). Gli1 suppression induces anoikis in ovarian cancer cells in vitro and blocks tumor formation ability in vivo. (J Biol Chem. – Under revision) 

• Kandala PK and Srivastava SK (2012). Diindolylmethane induces autophagy by activating ER stress and AMPK (Oncotarget – Under revision)

• Loganathan SK^*, Kandala PK^*, Gupta P and Srivastava SK (2012). Inhibition of EGFR-Akt axis results in the suppression of ovarian tumors in vitro and in preclinical mouse model. (PLoS ONE – Under revision) 

• Kandala PK and Srivastava SK (2012). JAK2 is a target of diindolylmethane in reducing the survival of ovarian cancer. (Drug discoveries and therapeutics – Under review).

Manuscripts under preparation:

 

•  Ravi P. Sahu, Prabodh K. Kandala, Srinivas Reddy Boreddy and Sanjay K. Srivastava (2012). Benzyl Isothiocyanate disrupts JAK3-STAT3-SOCS3 axis in pancreatic cancer cells (Under preparation).

 

•  Srinivas Reddy Boreddy, Prabodh K. Kandala and Sanjay K. Srivastava (2012). Critical role of autophagy proteins Beclin1 and LC3B in deguelin-induced apoptosis in pancreatic tumor cells in vitro and in vivo (Under preparation).

 

Published Abstracts & Poster Presentations

 

Published Abstracts

 

• Prabodh K. Kandala and Sanjay K. Srivastava. Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells.  Proc. Am. Assos. Can. Res. Vol 50, 2009. 
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 51, 2010
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas R. Boreddy and Sanjay K. Srivastava. 3,3’-diindolylmethane (DIM) induced apoptosis in ovarian tumors is mediated by inhibition of EGFR-ERK pathway. Proc. Am. Assos. Can. Res. Vol 51, 2010.
• Srinivas R. Boreddy, Kartick C. Pramanik, Prabodh K. Kandala and Sanjay K. Srivastava. Benzyl Isothiocynate suppresses pancreatic cancer invasion and angiogenesis by inhibiting PI3K/AKT and MMP2. Proc. Am. Assos. Can. Res. Vol 51, 2010.
• Kartick C. Pramanik, Srinivas R. Boreddy, Prabodh K. Kandala and Sanjay K. Srivastava. Involvement of mitochondrial respiratory chain in capsaicin mediated ROS generation in pancreatic cancer cells. Proc. Am. Assos. Can. Res. Vol 51, 2010
• Prabodh K. Kandala and Sanjay K. Srivastava (2011). Diindolylmethane potentiates the effect of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF. Proc. Am. Assos. Can. Res. Vol 52, 2011.
• Prabodh K. Kandala and Sanjay K. Srivastava (2011). Diindolylmethane induces ER stress mediated autophagy in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 52, 2011.
• Srinivas Reddy Boreddy, Prabodh K. Kandala, Kartick C. Pramanik, Parul Gupta and Sanjay K. Srivastava (2012). Critical role of autophagy proteins Beclin1 and LC3B in deguelin-induced apoptosis in pancreatic tumor cells in vitro and in vivo: A new paradigm. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Prabodh K. Kandala and Sanjay K. Srivastava (2012). DIM regulates anoikis through sonic hedgehog in ovarian cancer cells. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Prabodh K. Kandala and Sanjay K. Srivastava (2012). Blocking Janus activated kinase-2 activation by DIM suppresses ovarian tumor growth in vitro and in vivo. Proc. Am. Assos. Can. Res. Vol 53, 2012.
• Srinivas Reddy Boreddy, Prabodh K. Kandala, Parul Gupta and Sanjay K. Srivastava (2012). HDAC inhibition reverses EMT through modulation of ZEB1. Proc. Am. Assos. Can. Res. Vol 53, 2012.

Poster presentations

• Ravi P. Sahu, Prabodh K. Kandala*, Michael W. Epperly and Sanjay K. Srivastava at Research Week, TTUHSC, Lubbock. March 2008.
• 3,3′-Diindolylmethane, a dietary agent causes G2/M arrest by activating CHK2 in human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava.at Research Days , TTUHSC, Amarillo June 2008.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. TTUHSC Student Research Week, Lubbock, TX, 2009.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. AACR, Denver, CO. 4/2009.
• Activation of Chk2 by BR-DIM is required for causing G2/M arrest in Human ovarian cancer cells. Prabodh K. Kandala and Sanjay K. Srivastava. Research days, TTUHSC, Amarillo. June 2009.
• Embelin induces apoptosis in pancreatic cancer cells by inhibiting ERK survival pathway. Brandon T. Cooper, Prabodh K. Kandala and Sanjay K. Srivastava. ABRI Summer Intern Symposium, TTUHSC, Amarillo. July 2009.
• BITC suppresses the growth of kidney cancer cells by activating ERK and inhibiting STAT-3. Faiz Hussain, Prabodh K. Kandala and Sanjay K. Srivastava. WHRI Summer Intern Symposium, TTUHSC, Amarillo. July 2009.
• Chemotherapeutic Effects of Diindolylmethane against Ovarian Cancer. Oral Presentation given at International Symposium on Cancer Chemoprevention and Translational Research, New Delhi, India, 12/21/09.
• Prabodh K. Kandala and Sanjay K. Srivastava. Stat-3: A novel target of Diindolylmethane in Ovarian cancer. TTUHSC Student Research Week, Lubbock. 3/2010.
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. AACR, Washington DC. April 2010.
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas R. Boreddy and Sanjay K. Srivastava. 2. 3,3’-diindolylmethane (DIM) induced apoptosis in ovarian tumors is mediated by inhibition of EGFR-ERK pathway. AACR, Washington DC. April 2010. 
• Prabodh K. Kandala, Kartick C. Pramanik, Srinivas Reddy Boreddy and Sanjay K. Srivastava. 3,3′-Diindolylmethane (DIM)-Induced Apoptosis in Ovarian Tumors is Mediated by Inhibition of EGFR-ERK Pathway. Research Days, TTUHSC SOP Amarillo. 6/10.
• Prabodh K. Kandala and Sanjay K. Srivastava. STAT-3: a novel target of Diindolylmethane in ovarian cancer cells. Research Days, TTUHSC SOP Amarillo. 6/10.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane suppresses ovarian cancer and potentiates the effect of cisplatin in tumor mouse model by targeting STAT3. Annual GSBS Graduate Student & Mentor Retreat, Lubbock, TX. 1/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF. Student Research Week, TTUHSC Lubbock. 3/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells. Student Research Week, TTUHSC Lubbock. 3/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. AACR, Orlando. 4/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. AACR, Orlando. 4/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. TTUHSC 2011 Annual Cancer Symposium, Amarillo. 4/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. TTUHSC 2011 Annual Cancer Symposium, Amarillo. 4/11.
• Prabodh K. Kandala, Stephen E. Wright and Sanjay K. Srivastava. “Diindolylmethane potentiates the effects of cisplatin in ovarian cancer by inhibiting STAT-3 and VEGF”. Tenth Annual Research Days, Amarillo. 6/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. “Diindolylmethane (DIM) induces ER stress mediated autophagy in ovarian cancer cells”. Tenth Annual Research Days, Amarillo. 6/11.
• Prabodh K. Kandala and Sanjay K. Srivastava. Diindolylmethane induces macroautophagy by regulating ER stress and AMPK. AAPS, Wash DC. 10/11.
• Prabodh Kumar Kandala and Sanjay Srivastava. “Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling Glucose regulatory protein 78 and AMPK”. Annual GSBS TTU Student Recruitment Event, Lubbock. 1/17/12.

Leadership

• Graduate Students Association at Amarillo (GSAA). Vice-President 2009-10
• American Association of Pharmaceutical Scientists, Amarillo Chapter. Secretary, 2010-11.
• American Association of Pharmaceutical Scientists, Amarillo Chapter. Chair-elect, 2011-12

Community Service

•  Juvenile Diabetes Research Foundation walk participant (2008-11)
• March of Dimes walk participant (2007-11).
• American Heart Association walk participant (2007-11).
• American Heart Association Walk T-shirt fundraiser (2009).
• Volunteered Plains Foodbank blood drive (2008-11).
• Volunteer at Hispanic foundation, mentored a session on how to quit smoking (2009).
• Donorschoose.org. Monetary help that will support studies of underprivileged students (2010-current). 

Affiliations and Memberships

 

• American Association of Cancer Research (2008-current).
• American Association of Pharmaceutical Scientists (2007-current).
• The American Association of Advancement in Science (2008-current).
• National Association of Science Writers (2009-2011).
• Graduate Student Association at Amarillo (2007-current).
• The Global Leaders (2012-current).